Antibiotics in the clinical pipeline at the end of 2015
Citations
366 citations
Cites background from "Antibiotics in the clinical pipelin..."
...Brilacidin was first developed by Polymedix Inc. and purchased by Cellceutix corp. in September 2013 (Butler et al., 2017)....
[...]
...It also offers potential clinical advantages in the fight against emerging and antibiotic resistant bacterial infections (North et al., 2016) SGX-942 was first developed by Inimex and is currently being pursued in a Phase-II trial by Soligenix as treatment for oral mucositis (Butler et al., 2017)....
[...]
...LTX 109 is a synthetic antimicrobial peptidomimetic, which has completed phase 2 trials for the treatment of impetigo in the year 2014 and uncomplicated skin and skin structure infection (uSSSI) in the year 2011 (Butler et al., 2017)....
[...]
...Exeporfinium chloride (XF-73) is a synthetic dicationic porphyrin derivative being developed by Destiny Pharma (Brighton, UK) that has been evaluated in phase-I/II trials for the prevention of post-surgical staphylococcal nasal infections (Figure 4; Butler et al., 2017)....
[...]
..., 2016) SGX-942 was first developed by Inimex and is currently being pursued in a Phase-II trial by Soligenix as treatment for oral mucositis (Butler et al., 2017)....
[...]
295 citations
192 citations
186 citations
186 citations
Cites background from "Antibiotics in the clinical pipelin..."
...In phase III clinical trials there are only eight drugs with broad-spectrum activity, while phase II trials comprise ten broad-spectrum drugs of which only one targets Gram-negative pathogens, whereas there is only one broad-spectrum antibiotic in phase I trial [28]....
[...]
...According to FDA, between 2012 and 2017 only nine antibiotics were approved, of which none was first-in-class against Gram-negative pathogens [28]....
[...]
References
3,147 citations
2,228 citations
1,964 citations
929 citations
681 citations